Citations (59)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Alessia Villani, Massimiliano Scalvenzi, Giuseppe Micali, Fabrizio Martora, Francesco Cillo, Flavia Raia & Luca Potestio. (2023) An update on the current and emerging pharmacotherapies for basal cell carcinomas. Expert Opinion on Pharmacotherapy 0:0, pages 1-9.
Read now
Read now
Florian Herms & Nicole Basset-Seguin. (2021) Emerging drugs for the treatment of basal cell carcinoma. Expert Opinion on Emerging Drugs 26:1, pages 17-26.
Read now
Read now
Tohid Kazemi, Vahid Younesi, Farhad Jadidi-Niaragh & Mehdi Yousefi. (2016) Immunotherapeutic approaches for cancer therapy: An updated review. Artificial Cells, Nanomedicine, and Biotechnology 44:3, pages 769-779.
Read now
Read now
Jonathan Pol, Norma Bloy, Aitziber Buqué, Alexander Eggermont, Isabelle Cremer, Catherine Sautès-Fridman, Jérôme Galon, Eric Tartour, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2015) Trial Watch: Peptide-based anticancer vaccines. OncoImmunology 4:4.
Read now
Read now
Fernando Aranda, Erika Vacchelli, Florine Obrist, Alexander Eggermont, Jérôme Galon, Catherine Sautès-Fridman, Isabelle Cremer, Jan Henrik ter Meulen, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2014) Trial Watch. OncoImmunology 3:6.
Read now
Read now
Giuseppe Micali, Francesco Lacarrubba, Karishma Bhatt & Maria Rita Nasca. (2013) Medical approaches to non-melanoma skin cancer. Expert Review of Anticancer Therapy 13:12, pages 1409-1421.
Read now
Read now
Michael A Collier, Matthew D Gallovic, Kevin J Peine, Anthony D Duong, Eric M Bachelder, John S Gunn, Larry S Schlesinger & Kristy M Ainslie. (2013) Delivery of host cell-directed therapeutics for intracellular pathogen clearance. Expert Review of Anti-infective Therapy 11:11, pages 1225-1235.
Read now
Read now
Articles from other publishers (52)
Xiaoqiong Zhang, Zhaohan Wei, Tuying Yong, Shiyu Li, Nana Bie, Jianye Li, Xin Li, Haojie Liu, Hang Xu, Yuchen Yan, Bixiang Zhang, Xiaoping Chen, Xiangliang Yang & Lu Gan. (2023) Cell microparticles loaded with tumor antigen and resiquimod reprogram tumor-associated macrophages and promote stem-like CD8+ T cells to boost anti-PD-1 therapy. Nature Communications 14:1.
Crossref
Crossref
Jiali Sun, Zhilin Liu, Haochen Yao, Honglei Zhang, Mengfei Zheng, Na Shen, Jianjun Cheng, Zhaohui Tang & Xuesi Chen. (2023) Azide‐Masked Resiquimod Activated by Hypoxia for Selective Tumor Therapy. Advanced Materials 35:29.
Crossref
Crossref
Manuel Keppler, Simon Straß, Sophia Geiger, Tina Fischer, Nadja Späth, Thilo Weinstein, Anna Schwamborn, Jamil Guezguez, Jan-Hinrich Guse, Stefan Laufer & Michael Burnet. (2023) Imidazoquinolines with improved pharmacokinetic properties induce a high IFNα to TNFα ratio in vitro and in vivo. Frontiers in Immunology 14.
Crossref
Crossref
Bishal Misra, Krystal A. Hughes & Sharan Bobbala. 2023. Nanomedicines for the Prevention and Treatment of Infectious Diseases. Nanomedicines for the Prevention and Treatment of Infectious Diseases
297
330
.
Nimish Gupta, G. D. Gupta & Dilpreet Singh. (2022) Localized topical drug delivery systems for skin cancer: Current approaches and future prospects. Frontiers in Nanotechnology 4.
Crossref
Crossref
Zhi-Mei Liu, Ming-Hui Yang, Kun Yu, Zheng-Xing Lian & Shou-Long Deng. (2022) Toll-like receptor (TLRs) agonists and antagonists for COVID-19 treatments. Frontiers in Pharmacology 13.
Crossref
Crossref
Ramya Mathiyalagan, Anjali Kariyarath Valappil, Deok Chun Yang, Se Chan Kang & Thavasyappan Thambi. (2022) Gene Regulations upon Hydrogel-Mediated Drug Delivery Systems in Skin Cancers—An Overview. Gels 8:9, pages 560.
Crossref
Crossref
David Taylor, Christian T. Meyer, Diana Graves, Rupashree Sen, Juan Fu, Emily Tran, Bilal Mirza, Gabriel Rodriguez, Cara Lang, Hanwen Feng, Vito Quaranta, John T. Wilson, Young J. Kim & Michael J. Korrer. (2022) MuSyC dosing of adjuvanted cancer vaccines optimizes antitumor responses. Frontiers in Immunology 13.
Crossref
Crossref
Qian Luo, John V. Napoleon, Xin Liu, Boning Zhang, Suilan Zheng & Philip S. Low. (2022) Targeted Rejuvenation of Exhausted Chimeric Antigen Receptor T Cells Regresses Refractory Solid Tumors. Molecular Cancer Research 20:5, pages 823-833.
Crossref
Crossref
Xiao Li, Xinyuan Sun, Xuemin Guo, Xueren Li, Shouchun Peng & Xin Mu. (2022) Chemical reagents modulate nucleic acid-activated toll-like receptors. Biomedicine & Pharmacotherapy 147, pages 112622.
Crossref
Crossref
Hin Chu & Jasper Fuk-Woo Chan. (2021) A lethal mouse model using a mouse-adapted SARS-CoV-2 strain with enhanced binding to mouse ACE2 as an important platform for COVID-19 research. EBioMedicine 68, pages 103406.
Crossref
Crossref
Dina V. Hingorani, Maria F. Camargo, Maryam A. Quraishi, Stephen R. Adams & Sunil J. Advani. (2021) Tumor Activated Cell Penetrating Peptides to Selectively Deliver Immune Modulatory Drugs. Pharmaceutics 13:3, pages 365.
Crossref
Crossref
Matteo Conti. 2020. Drug Repurposing - Hypothesis, Molecular Aspects and Therapeutic Applications. Drug Repurposing - Hypothesis, Molecular Aspects and Therapeutic Applications.
Asunción Espinosa-Sánchez, Elisa Suárez-Martínez, Laura Sánchez-Díaz & Amancio Carnero. (2020) Therapeutic Targeting of Signaling Pathways Related to Cancer Stemness. Frontiers in Oncology 10.
Crossref
Crossref
Cindy Patinote, Nour Bou Karroum, Georges Moarbess, Natalina Cirnat, Issam Kassab, Pierre-Antoine Bonnet & Carine Deleuze-Masquéfa. (2020) Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes. European Journal of Medicinal Chemistry 193, pages 112238.
Crossref
Crossref
Lisa Kötzner, Bayard Huck, Sakshi Garg & Klaus Urbahns. 2020.
1
62
.
Francisco A. Venegas, Gabriele Köllisch, Kerstin Mark, Wibke E. Diederich, Andreas Kaufmann, Stefan Bauer, Max Chavarría, Juan J. Araya & Alfonso J. García-Piñeres. (2019) The Bacterial Product Violacein Exerts an Immunostimulatory Effect Via TLR8. Scientific Reports 9:1.
Crossref
Crossref
Sandra Vreman, Joanne McCaffrey, Ditta J. Popma-de Graaf, Hans Nauwynck, Huub F.J. Savelkoul, Anne Moore, Johanna M.J. Rebel & Norbert Stockhofe-Zurwieden. (2019) Toll-like receptor agonists as adjuvants for inactivated porcine reproductive and respiratory syndrome virus (PRRSV) vaccine. Veterinary Immunology and Immunopathology 212, pages 27-37.
Crossref
Crossref
Cédric Thauvin, Jérôme Widmer, Inès Mottas, Sandra Hocevar, Eric Allémann, Carole Bourquin & Florence Delie. (2019) Development of resiquimod-loaded modified PLA-based nanoparticles for cancer immunotherapy: A kinetic study. European Journal of Pharmaceutics and Biopharmaceutics 139, pages 253-261.
Crossref
Crossref
E. Stockfleth, G.F.L. Hofbauer, U. Reinhold, G. Popp, U.R. Hengge, R.M. Szeimies, H. Brüning, M. Anliker, T. Hunger, R. Dummer, C. Ulrich, R. Kenzelmann, C. Surber & L.E. French. (2018) Topical resiquimod dosing regimens in patients with multiple actinic keratoses: a multicentre, partly placebo‐controlled, double‐blind clinical trial. British Journal of Dermatology 180:2, pages 297-305.
Crossref
Crossref
Alexander Wilkinson, Eric Lattmann, Carla B. Roces, Gabriel K. Pedersen, Dennis Christensen & Yvonne Perrie. (2018) Lipid conjugation of TLR7 agonist Resiquimod ensures co-delivery with the liposomal Cationic Adjuvant Formulation 01 (CAF01) but does not enhance immunopotentiation compared to non-conjugated Resiquimod+CAF01. Journal of Controlled Release 291, pages 1-10.
Crossref
Crossref
Maryam A. Shetab Boushehri & Alf Lamprecht. (2018) TLR4-Based Immunotherapeutics in Cancer: A Review of the Achievements and Shortcomings. Molecular Pharmaceutics 15:11, pages 4777-4800.
Crossref
Crossref
Marc J. Braunstein, John Kucharczyk & Sylvia Adams. (2018) Targeting Toll-Like Receptors for Cancer Therapy. Targeted Oncology 13:5, pages 583-598.
Crossref
Crossref
Bayard R. Huck, Lisa Kötzner & Klaus Urbahns. (2018) Small Molecules Drive Big Improvements in Immuno‐Oncology Therapies. Angewandte Chemie International Edition 57:16, pages 4412-4428.
Crossref
Crossref
Bayard R. Huck, Lisa Kötzner & Klaus Urbahns. (2018) Kleine Moleküle, ganz groß: niedermolekulare immunonkologische Kombinationstherapien. Angewandte Chemie 130:16, pages 4499-4516.
Crossref
Crossref
Naoto Nishii, Hidetake Tachinami, Yuta Kondo, Yulong Xia, Yoshihisa Kashima, Tatsukuni Ohno, Shigenori Nagai, Lixin Li, Walter Lau, Hiroyuki Harada & Miyuki Azuma. (2018) Systemic administration of a TLR7 agonist attenuates regulatory T cells by dendritic cell modification and overcomes resistance to PD-L1 blockade therapy. Oncotarget 9:17, pages 13301-13312.
Crossref
Crossref
Francesco Gentile, Marco Deriu, Khaled Barakat, Andrea Danani & Jack Tuszynski. (2018) A Novel Interaction Between the TLR7 and a Colchicine Derivative Revealed Through a Computational and Experimental Study. Pharmaceuticals 11:1, pages 22.
Crossref
Crossref
Meng-Hsiun Tsai, Kai-Cheng Chuan, Jeng-Jer Shieh, Chia-Tsen Tsai, Yong-Zhi Huang & Tu-Wei Li. (2018) Microarray Data Analysis and Model Construction Based on Oversampling Approach and Decision Tree. Microarray Data Analysis and Model Construction Based on Oversampling Approach and Decision Tree.
Sandy R. Larson & Shaikh Muhammad Atif. 2018. Encyclopedia of Signaling Molecules. Encyclopedia of Signaling Molecules
5492
5498
.
Marco A. Deriu, Michela Cangiotti, Gianvito Grasso, Ginevra Licandro, Afsaneh Lavasanifar, Jack A. Tuszynski, Maria Francesca Ottaviani & Andrea Danani. (2017) Self-Assembled Ligands Targeting TLR7: A Molecular Level Investigation. Langmuir 33:50, pages 14460-14471.
Crossref
Crossref
Yao Mawulikplimi Adzavon, Pengxiang Zhao, Baobei Lv, Mengyu Liu, Xin Zhang, Fei Xie, Linqi Yang, Lei Shang, Mingzi Zhang, Qinjian Li & Xuemei Ma. (2017) TLR7 and TLR8 agonist resiquimod (R848) differently regulates MIF expression in cells and organs. Cytokine 97, pages 156-166.
Crossref
Crossref
Bert Müller & Marcel Van de VoordeKathrin Scherer Hofmeier & Christian Surber. 2017. Nanoscience and Nanotechnology for Human Health. Nanoscience and Nanotechnology for Human Health
329
356
.
Ilaria Coati, Serena Miotto, Irene Zanetti & Mauro Alaibac. (2016) Toll-like receptors and cutaneous melanoma. Oncology Letters 12:5, pages 3655-3661.
Crossref
Crossref
Jason G. Kettle, Husam Alwan, Michal Bista, Jason Breed, Nichola L. Davies, Kay Eckersley, Shaun Fillery, Kevin M. Foote, Louise Goodwin, David R. Jones, Helena Käck, Alan Lau, J. Willem M. Nissink, Jon Read, James S. Scott, Ben Taylor, Graeme Walker, Lisa Wissler & Marta Wylot. (2016) Potent and Selective Inhibitors of MTH1 Probe Its Role in Cancer Cell Survival. Journal of Medicinal Chemistry 59:6, pages 2346-2361.
Crossref
Crossref
Keith BiggadikeMahbub AhmedDoug I. BallDiane M. CoeDeidre A. Dalmas Wilk, Chris D. EdwardsBob H. GibbonCharlotte J. HardyStephen A. HermitageJoanne O. HesseyAimee E. Hillegas, Stephen C. HughesLinos LazaridesXiao Q. LewellAmanda LucasDavid N. MallettMark A. PriceFiona M. PriestDiana J. QuintPoonam ShahAnesh SitaramStephen A. SmithRichard StockerNaimisha A. TrivediDaphne C. TsitouraVictoria Weller. (2016)
Discovery of 6-Amino-2-{[(1
S
)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8
H
-purin-8-one (GSK2245035), a Highly Potent and Selective Intranasal Toll-Like Receptor 7 Agonist for the Treatment of Asthma
. Journal of Medicinal Chemistry 59:5, pages 1711-1726.
Crossref
Crossref
Nina Salabert, Biliana Todorova, Frédéric Martinon, Raphaël Boisgard, Gerard Zurawski, Sandra Zurawski, Nathalie Dereuddre-Bosquet, Antonio Cosma, Thierry Kortulewski, Jacques Banchereau, Yves Levy, Roger Le Grand & Catherine Chapon. (2016) Intradermal injection of an anti-Langerin-HIVGag fusion vaccine targets epidermal Langerhans cells in nonhuman primates and can be tracked in vivo. European Journal of Immunology 46:3, pages 689-700.
Crossref
Crossref
Anthony D. Duong, Michael A. Collier, Eric M. Bachelder, Barbra E. Wyslouzil & Kristy M. Ainslie. (2015) One Step Encapsulation of Small Molecule Drugs in Liposomes via Electrospray-Remote Loading. Molecular Pharmaceutics 13:1, pages 92-99.
Crossref
Crossref
Ronghua Liu, Feifei Luo, Xiaoming Liu, Luman Wang, Jiao Yang, Yuting Deng, Enyu Huang, Jiawen Qian, Zhou Lu, Xuechao Jiang, Dan Zhang & Yiwei Chu. 2016. Progress in Cancer Immunotherapy. Progress in Cancer Immunotherapy
69
138
.
Sandy R Larson & Shaikh Muhammad Atif. 2017. Encyclopedia of Signaling Molecules. Encyclopedia of Signaling Molecules
1
7
.
Hiroyuki Shinchi, Brian Crain, Shiyin Yao, Michael Chan, Shannon S. Zhang, Alast Ahmadiiveli, Yasuo Suda, Tomoko Hayashi, Howard B. Cottam & Dennis A. Carson. (2015) Enhancement of the Immunostimulatory Activity of a TLR7 Ligand by Conjugation to Polysaccharides. Bioconjugate Chemistry 26:8, pages 1713-1723.
Crossref
Crossref
Francesco Gentile, Marco Deriu, Ginevra Licandro, Alessio Prunotto, Andrea Danani & Jack Tuszynski. (2015) Structure Based Modeling of Small Molecules Binding to the TLR7 by Atomistic Level Simulations. Molecules 20:5, pages 8316-8340.
Crossref
Crossref
Osmarie Martínez, Eric Miranda, Maite Ramírez, Saritza Santos, Carlos Rivera, Luis Vázquez, Tomás Sánchez, Raymond L. Tremblay, Eddy Ríos-Olivares & Miguel Otero. (2015) Immunomodulator-Based Enhancement of Anti Smallpox Immune Responses. PLOS ONE 10:4, pages e0123113.
Crossref
Crossref
Rachel Lubong Sabado, Anna Pavlick, Sacha Gnjatic, Crystal M. Cruz, Isabelita Vengco, Farah Hasan, Meredith Spadaccia, Farbod Darvishian, Luis Chiriboga, Rose Marie Holman, Juliet Escalon, Caroline Muren, Crystal Escano, Ethel Yepes, Dunbar Sharpe, John P. Vasilakos, Linda Rolnitzsky, Judith D. Goldberg, John Mandeli, Sylvia Adams, Achim Jungbluth, Linda Pan, Ralph Venhaus, Patrick A. Ott & Nina Bhardwaj. (2015) Resiquimod as an Immunologic Adjuvant for NY-ESO-1 Protein Vaccination in Patients with High-Risk Melanoma. Cancer Immunology Research 3:3, pages 278-287.
Crossref
Crossref
Monika Chauhan, Anil Rana, Jimi Marin Alex, Arvind Negi, Sandeep Singh & Raj Kumar. (2015) Design, microwave-mediated synthesis and biological evaluation of novel 4-aryl(alkyl)amino-3-nitroquinoline and 2,4-diaryl(dialkyl)amino-3-nitroquinolines as anticancer agents. Bioorganic Chemistry 58, pages 1-10.
Crossref
Crossref
Samira Khiar, Nicolas Pietrancosta & Pierre-Olivier Vidalain. (2015) Stimuler la réponse interféron de type I avec des petites molécules : le renouveau d’une vieille idée. Biologie Aujourd'hui 209:2, pages 145-159.
Crossref
Crossref
Raphael Dolin. 2015. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases
576
580.e2
.
Raphael Dolin. 2015. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases
528
530
.
Emily Funk, Shyam Kottilil, Bruce Gilliam & Rohit Talwani. (2014) Tickling the TLR7 to cure viral hepatitis. Journal of Translational Medicine 12:1.
Crossref
Crossref
Ruey-Shyang Soong, Liwen Song, Janson Trieu, Jayne Knoff, Liangmei He, Ya-Chea Tsai, Warner Huh, Yung-Nien Chang, Wen-Fang Cheng, Richard B.S. Roden, T.-C. Wu, Cornelia L. Trimble & Chien-Fu Hung. (2014) Toll-like Receptor Agonist Imiquimod Facilitates Antigen-Specific CD8+ T-cell Accumulation in the Genital Tract Leading to Tumor Control through IFNγ. Clinical Cancer Research 20:21, pages 5456-5467.
Crossref
Crossref
Giuseppe Micali, Francesco Lacarrubba, Maria Rita Nasca & Robert A. Schwartz. (2014) Topical pharmacotherapy for skin cancer. Journal of the American Academy of Dermatology 70:6, pages 965.e1-965.e12.
Crossref
Crossref
Elke Bergmann-Leitner & Wolfgang Leitner. (2014) Adjuvants in the Driver’s Seat: How Magnitude, Type, Fine Specificity and Longevity of Immune Responses Are Driven by Distinct Classes of Immune Potentiators. Vaccines 2:2, pages 252-296.
Crossref
Crossref
Saskia Stier, Claudia Maletzki, Ulrike Klier & Michael Linnebacher. (2013) Combinations of TLR Ligands: A Promising Approach in Cancer Immunotherapy. Clinical and Developmental Immunology 2013, pages 1-14.
Crossref
Crossref